Trials / Terminated
TerminatedNCT01077297
Tezosentan in Pulmonary Arterial Hypertension
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Idorsia Pharmaceuticals Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, Open-label, Non-comparative, Proof-of-concept, Phase 2a Study to Evaluate the Effect of a Single Infusion of Tezosentan on Pulmonary Vascular Resistance in Patients With Stable, Chronic Pulmonary Arterial Hypertension, Currently Not Treated With Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors or Prostacyclines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tezosentan | single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2010-11-01
- Completion
- 2011-09-01
- First posted
- 2010-03-01
- Last updated
- 2018-07-09
Locations
5 sites across 3 countries: United States, France, Switzerland
Source: ClinicalTrials.gov record NCT01077297. Inclusion in this directory is not an endorsement.